Avenue Therapeutics Receives Complete Response Letter from …
https://ir.avenuetx.com/news-events/press-releases/detail/10/avenue-therapeutics-receives-complete-response-letter-from
webNEW YORK, June 14, 2021 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ: ATXI) (“Avenue”), a company focused on the development of intravenous (“IV”) tramadol for the U.S. market, today announced that it has received a second Complete Response Letter (“CRL”) from the U.S. Food and Drug Administration (“FDA”) regarding its ...
DA: 55 PA: 62 MOZ Rank: 25